The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The approval covers pediatric patients without a matched sibling donor for stem cell transplant
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
It promises fewer injections for vision loss patients
Call it a major breakthrough for diagnostic imaging
Subscribe To Our Newsletter & Stay Updated
